Showing 2640 results
- Story /
Novartis researchers are using data to accelerate drug development.
- Story /
- Story /
An interview with Thierry Diagana, Head of the Novartis Institute for Tropical Diseases.
- Media Release /Phase 3 ASCLEPIOS I/II trials and the ALITHIOS open-label extension demonstrated the efficacy and safety of continuous Kesimpta® (ofatumumab) treatment and in those switched from teriflunomide, with…
- Media Release /Clearance of critical milestone expands capability for production of gene therapies, starting with Zolgensma® Basel, April 5, 2022 – Novartis today announced the U.S. Food and Drug Administration (…
- Media Release /Vijoice is first approved treatment to specifically address the root cause of PROS conditions in select patients 2 years of age and older1 PROS is a spectrum of rare conditions and is…
- Media Release /Lenalidomide Sandoz is indicated for use in several critical haematology-oncology conditions, per latest ESMO guidelines1,4Cost savings from Lenalidomide Sandoz can expand treatment options for…
- Key Release /Ad hoc announcement pursuant to Art. 53 LR Q4 sales grew +6% (cc1, +4% USD) and core operating income grew +12% (cc, +9% USD) IM sales grew +7% (cc, +5% USD) and core operating income +15% (cc, +12…
- Statement /
- Featured News /
Novartis announces the company’s fourth quarter and 2021 full year financial results.
Pagination
- ‹ Previous page
- 1
- …
- 154
- 155
- 156
- 157
- 158
- 159
- 160
- …
- 264
- › Next page